In humans, increased levels of plasma FGF21 can predict metabolic syndrome and type 2 diabetes in healthy subjects, and are associated with insulin resistance, metabolic syndrome, type 2 diabetes, NAFLD and an increased risk of CVD. Here, FGF21 is linked to type 2 diabetes mellitus.